# Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

> **NCT05130177** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Diwakar Davar** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Domvanalimab

## Key facts

- **NCT ID:** NCT05130177
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-16
- **Primary completion:** 2026-02-06
- **Final completion:** 2030-01-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130177, "Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05130177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*